Suchergebnisse

This book is the history of an imaginary people - the Red Jews - in vernacular sources from medieval and early modern Germany. From the twelfth to the seventeenth century, German-language texts repeated and embroidered on an antisemitic tale concerning an epochal threat to Christianity, the Red Jews. This term, which expresses a medieval conflation of three separate traditions (the biblical destroyers Gog and Magog, the 'unclean peoples' enclosed by Alexander, and the Ten Lost Tribes of Israel), is a hostile designation of wickedness. The Red Jews played a major role in late medieval popular exegesis and literature, and appeared in a hitherto-unnoticed series of sixteenth-century pamphlets, in which they functioned as the medieval 'spectacles' through which contemporaries viewed such events as Turkish advances in the Near and Middle East. The Red Jews disappear from the sources after 1600, and consequently never found their way into historical scholarship

Gender at stake critiques historians' assumptions about witch-hunting as well as their explanations for this complex and perplexing phenomenon. The authors insist on the centrality of gender, tradition and ideas about witches in the construction of the witch as a dangerous figure. They challenge the marginalisation of male witches by feminist and other historians. The book shows that large numbers of men were accused of witchcraft in their own right, in some regions, more men were accused than women. The authors analyse ideas about witches and witch prosecution as gendered artefacts of patriarchal societies under which both women and men suffered. They challenge recent arguments and current orthodoxies by applying crucial insights from feminist scholarship on gender to a selection of statistical arguments, social-historical explanations, traditional feminist history and primary sources, including trial records and demonological literature. The authors assessment of current orthodoxies concerning the causes and origins of witch-hunting will be of particular interest to scholars and students in undergraduate and graduate courses in early modern history, religion, culture, gender studies and methodology

Reflection on Sloexit can inform consideration of the "Brexit" question, notwithstanding the inevitable dissimilarities between the cases. Independence from a union of sovereign states in both cases, where formal sovereign rights in some areas had been transferred to that union and decision making was inter-governmental, provide a point of reference for comparative insight in terms of economic collapse, structural disjuncture, and pressures of demographic change and migration in the two inter-governmental frameworks and the different periods. There were three major negative impacts caused by Sloexit: sharp economic decline; a significant decline in trade and industry, particularly affecting businesses significantly active in the union, leading to restructuring, losses and closures; and, last, perceived uncertainty and insecurity, making international loans and credit difficult to secure, and inhibiting foreign direct investment. These were effects that might well affect the UK, in one way, or another. In the final analysis, Slovenia's independence was survivable, but carried a high cost economically and, also, arguably, the armed conflict that afflicted other Yugoslav states. The Slovenian example demonstrates the way in which actions prompt reactions and lock parties into a particular trajectory. Assertions of sovereignty reap counter-assertions of sovereignty and can generate unknown outcomes and the effects on the actors themselves will be unpredictable. It is a caution, in the context of discussion about the UK's leaving the EU, to keep in mind that separations are hard and that being rejected by being 'left' almost inevitably creates resentments, even where there is good will.

Severe asthma is a subtype of asthma that is difficult to treat and control. By conservative estimates, severe asthma affects approximately 5–10% of patients with asthma worldwide. Severe asthma impairs patients' health-related quality of life, and patients are at risk of life-threatening asthma attacks. Severe asthma also accounts for the majority of health care expenditures associated with asthma. Guidelines recommend that patients with severe asthma be referred to a specialist respiratory team for correct diagnosis and expert management. This is particularly important to ensure that they have access to newly available biologic treatments. However, many patients with severe asthma can suffer multiple asthma attacks and wait several years before they are referred for specialist care. As global patient advocates, we believe it is essential to raise awareness and understanding for patients, caregivers, health care professionals, and the public about the substantial impact of severe asthma and to create opportunities for improving patient care. Patients should be empowered to live a life free of symptoms and the adverse effects of traditional medications (e.g., oral corticosteroids), reducing hospital visits and emergency care, the loss of school and work days, and the constraints placed on their daily lives. Here we provide a Patient Charter for severe asthma, consisting of six core principles, to mobilize national governments, health care providers, payer policymakers, lung health industry partners, and patients/caregivers to address the unmet need and burden in severe asthma and ultimately work together to deliver meaningful improvements in care.

Acknowledgements The authors thank the following individuals who contributed to the initial set-up of ISAR, provided input to the development of the protocol and/or were involved in local implementation of ISAR: Elisabeth Bel, Roland Buhl, Sverre Lehmann, Stelios Loukidis, Richard Martin, Juno Pak, Pearlanne Zelar ney, Joy Zimmer, Christena Kolakowski, Margo Brown, Jessica Cummings, Jennifer Brandorff, Seth Skelton, John Upham, Philip Bardin, Paul Reynolds, David Langton, Peter Middleton, Belinda Cochrane, Katya Vasileva Noleva, Plamen Hristov Yakovliev, Sonya Metodieva Genova, Violina Milchova Vasi leva, Darina Petrova Dimova, Nadezhda K Takovska, Cvetantka Hristova Odz hakova, Eleonora M Stamenova, Diana X Hristova, Vincente Plaza, Ian Hirsch, Cekomir Vodenicharov, Alexandrina Vodenicharova and Magdalena Alexandrova. Medical writing support was provided by Michelle Rebello, PhD, and Liam Gillies, PhD, of Cactus Communications (Mumbai, India). Funding The International Severe Asthma Registry is conducted by Optimum Patient Care Global Limited, and co-funded by Optimum Patient Care Global Limited and AstraZeneca. ISAR is supported by grants from AstraZeneca and Optimum Patient Care (OPC) Global (a not-for-profit social enterprise). The ISAR steering committee (ISC) was involved in the development of the protocol and is responsible for approving research proposals via a democratic voting process. In addition to 47 clinicians and researchers with an interest and experience in severe asthma, the ISC also includes members of OPC and four medical experts from AstraZeneca. AstraZeneca reviewed the draft before submission; however, decision to submit was made by the authors. Medical writing support was funded by AstraZeneca in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). ; Peer reviewed ; Publisher PDF

Publisher's version (útgefin grein) ; Background: Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical features and outcomes of severe asthma in order to facilitate personalised and targeted care. The International Severe Asthma Registry (ISAR) is a multi-country registry project initiated to aid in this endeavour. Methods: ISAR is a multi-disciplinary initiative benefitting from the combined experience of the ISAR Steering Committee (ISC; comprising 47 clinicians and researchers across 29 countries, who have a special interest and/or experience in severe asthma management or establishment and maintenance of severe asthma registries) in collaboration with scientists and experts in database management and communication. Patients (=18 years old) receiving treatment according to the 2018 definitions of the Global Initiative for Asthma (GINA) Step 5 or uncontrolled on GINA Step 4 treatment will be included. Data will be collected on a core set of 95 variables identified using the Delphi method. Participating registries will agree to provide access to and share standardised anonymous patient-level data with ISAR. ISAR is a registered data source on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ISAR's collaborators include Optimum Patient Care, the Respiratory Effectiveness Group (REG) and AstraZeneca. ISAR is overseen by the ISC, REG, the Anonymised Data Ethics and Protocol Transparency Committee and the ISAR operational committee, ensuring the conduct of ethical, clinically relevant research that brings value to all key stakeholders. Conclusions: ISAR aims to offer a rich source of real-life data for scientific research to understand and improve disease burden, treatment patterns and patient outcomes in severe asthma. Furthermore, the registry will provide an international platform for research collaboration in respiratory medicine, with the overarching aim of improving primary and secondary care of adults with severe asthma globally. ; The International Severe Asthma Registry is conducted by Optimum Patient Care Global Limited, and co-funded by Optimum Patient Care Global Limited and AstraZeneca. ISAR is supported by grants from AstraZeneca and Optimum Patient Care (OPC) Global (a not-for-profit social enterprise). The ISAR steering committee (ISC) was involved in the development of the protocol and is responsible for approving research proposals via a democratic voting process. In addition to 47 clinicians and researchers with an interest and experience in severe asthma, the ISC also includes members of OPC and four medical experts from AstraZeneca. AstraZeneca reviewed the draft before submission; however, decision to submit was made by the authors. Medical writing support was funded by AstraZeneca in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). ; Peer Reviewed